世界の先天性高インスリン症治療薬市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)

GlobalInfoResearchが発行した調査報告書(GIR21JY00001)
◆英語タイトル:Global Congenital Hyperinsulinism Treatment Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026
◆商品コード:GIR21JY00001
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2021年7月(※2024年版があります。お問い合わせください。)
◆ページ数:93
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2~3日)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

GlobalInfoResearch社の本調査レポートでは、先天性高インスリン症治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。先天性高インスリン症治療薬の種類別市場規模(ジアゾキシド、オクトレオチド、グルカゴン)、用途別市場規模(病院、クリニック、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・メーカー情報(企業概要、製品概要、販売量、価格、売上):Novo Nordisk、Eli Lilly、Fresenius Kabi、Taj Pharmaceuticals、Xeris Pharmaceuticals、Novartis、IVAX Pharmaceuticals、Sun Pharmaceutical、Chengdu Tiantaishan Pharmaceutical、Sihuan Pharmaceutical Holdings Group
・メーカー別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:ジアゾキシド、オクトレオチド、グルカゴン
・用途別分析2016年-2026年:病院、クリニック、その他
・先天性高インスリン症治療薬の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・先天性高インスリン症治療薬のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・先天性高インスリン症治療薬のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・先天性高インスリン症治療薬の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・先天性高インスリン症治療薬の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
【レポートの概要】

The Congenital Hyperinsulinism Treatment Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Congenital Hyperinsulinism Treatment Drugs size is estimated to be USD XX million in 2026 from USD XX million in 2020, with a change XX% between 2020 and 2021. The global Congenital Hyperinsulinism Treatment Drugs market size is expected to grow at a CAGR of XX% for the next five years.

Market segmentation
Congenital Hyperinsulinism Treatment Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Diazoxide
Octreotide
Glucagon

Market segment by Application, can be divided into
Hospital
Clinic
Other

Market segment by players, this report covers
Novo Nordisk
Eli Lilly
Fresenius Kabi
Taj Pharmaceuticals
Xeris Pharmaceuticals
Novartis
IVAX Pharmaceuticals
Sun Pharmaceutical
Chengdu Tiantaishan Pharmaceutical
Sihuan Pharmaceutical Holdings Group

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Congenital Hyperinsulinism Treatment Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Congenital Hyperinsulinism Treatment Drugs, with revenue, gross margin and global market share of Congenital Hyperinsulinism Treatment Drugs from 2019 to 2021.
Chapter 3, the Congenital Hyperinsulinism Treatment Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Congenital Hyperinsulinism Treatment Drugs market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Congenital Hyperinsulinism Treatment Drugs research findings and conclusion, appendix and data source.

【レポートの目次】

1 Market Overview
1.1 Product Overview and Scope of Congenital Hyperinsulinism Treatment Drugs
1.2 Classification of Congenital Hyperinsulinism Treatment Drugs by Type
1.2.1 Overview: Global Congenital Hyperinsulinism Treatment Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share by Type in 2020
1.2.3 Diazoxide
1.2.4 Octreotide
1.2.5 Glucagon
1.3 Global Congenital Hyperinsulinism Treatment Drugs Market by Application
1.3.1 Overview: Global Congenital Hyperinsulinism Treatment Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Congenital Hyperinsulinism Treatment Drugs Market Size & Forecast
1.5 Global Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast by Region
1.5.1 Global Congenital Hyperinsulinism Treatment Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Congenital Hyperinsulinism Treatment Drugs Market Size by Region, (2016-2021)
1.5.3 North America Congenital Hyperinsulinism Treatment Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Congenital Hyperinsulinism Treatment Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Congenital Hyperinsulinism Treatment Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Congenital Hyperinsulinism Treatment Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Congenital Hyperinsulinism Treatment Drugs Market Drivers
1.6.2 Congenital Hyperinsulinism Treatment Drugs Market Restraints
1.6.3 Congenital Hyperinsulinism Treatment Drugs Trends Analysis
2 Company Profiles
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk Congenital Hyperinsulinism Treatment Drugs Product and Solutions
2.1.4 Novo Nordisk Congenital Hyperinsulinism Treatment Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Novo Nordisk Recent Developments and Future Plans
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly Congenital Hyperinsulinism Treatment Drugs Product and Solutions
2.2.4 Eli Lilly Congenital Hyperinsulinism Treatment Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Eli Lilly Recent Developments and Future Plans
2.3 Fresenius Kabi
2.3.1 Fresenius Kabi Details
2.3.2 Fresenius Kabi Major Business
2.3.3 Fresenius Kabi Congenital Hyperinsulinism Treatment Drugs Product and Solutions
2.3.4 Fresenius Kabi Congenital Hyperinsulinism Treatment Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Fresenius Kabi Recent Developments and Future Plans
2.4 Taj Pharmaceuticals
2.4.1 Taj Pharmaceuticals Details
2.4.2 Taj Pharmaceuticals Major Business
2.4.3 Taj Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Product and Solutions
2.4.4 Taj Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Taj Pharmaceuticals Recent Developments and Future Plans
2.5 Xeris Pharmaceuticals
2.5.1 Xeris Pharmaceuticals Details
2.5.2 Xeris Pharmaceuticals Major Business
2.5.3 Xeris Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Product and Solutions
2.5.4 Xeris Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Xeris Pharmaceuticals Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Congenital Hyperinsulinism Treatment Drugs Product and Solutions
2.6.4 Novartis Congenital Hyperinsulinism Treatment Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Novartis Recent Developments and Future Plans
2.7 IVAX Pharmaceuticals
2.7.1 IVAX Pharmaceuticals Details
2.7.2 IVAX Pharmaceuticals Major Business
2.7.3 IVAX Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Product and Solutions
2.7.4 IVAX Pharmaceuticals Congenital Hyperinsulinism Treatment Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 IVAX Pharmaceuticals Recent Developments and Future Plans
2.8 Sun Pharmaceutical
2.8.1 Sun Pharmaceutical Details
2.8.2 Sun Pharmaceutical Major Business
2.8.3 Sun Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Product and Solutions
2.8.4 Sun Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sun Pharmaceutical Recent Developments and Future Plans
2.9 Chengdu Tiantaishan Pharmaceutical
2.9.1 Chengdu Tiantaishan Pharmaceutical Details
2.9.2 Chengdu Tiantaishan Pharmaceutical Major Business
2.9.3 Chengdu Tiantaishan Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Product and Solutions
2.9.4 Chengdu Tiantaishan Pharmaceutical Congenital Hyperinsulinism Treatment Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Chengdu Tiantaishan Pharmaceutical Recent Developments and Future Plans
2.10 Sihuan Pharmaceutical Holdings Group
2.10.1 Sihuan Pharmaceutical Holdings Group Details
2.10.2 Sihuan Pharmaceutical Holdings Group Major Business
2.10.3 Sihuan Pharmaceutical Holdings Group Congenital Hyperinsulinism Treatment Drugs Product and Solutions
2.10.4 Sihuan Pharmaceutical Holdings Group Congenital Hyperinsulinism Treatment Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Sihuan Pharmaceutical Holdings Group Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Congenital Hyperinsulinism Treatment Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Congenital Hyperinsulinism Treatment Drugs Players Market Share
3.2.2 Top 10 Congenital Hyperinsulinism Treatment Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Congenital Hyperinsulinism Treatment Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Congenital Hyperinsulinism Treatment Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Congenital Hyperinsulinism Treatment Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Congenital Hyperinsulinism Treatment Drugs Revenue Market Share by Application (2016-2021)
5.2 Congenital Hyperinsulinism Treatment Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Congenital Hyperinsulinism Treatment Drugs Revenue by Type (2016-2026)
6.2 North America Congenital Hyperinsulinism Treatment Drugs Revenue by Application (2016-2026)
6.3 North America Congenital Hyperinsulinism Treatment Drugs Market Size by Country
6.3.1 North America Congenital Hyperinsulinism Treatment Drugs Revenue by Country (2016-2026)
6.3.2 United States Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Congenital Hyperinsulinism Treatment Drugs Revenue by Type (2016-2026)
7.2 Europe Congenital Hyperinsulinism Treatment Drugs Revenue by Application (2016-2026)
7.3 Europe Congenital Hyperinsulinism Treatment Drugs Market Size by Country
7.3.1 Europe Congenital Hyperinsulinism Treatment Drugs Revenue by Country (2016-2026)
7.3.2 Germany Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
7.3.3 France Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Market Size by Region
8.3.1 Asia-Pacific Congenital Hyperinsulinism Treatment Drugs Revenue by Region (2016-2026)
8.3.2 China Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
8.3.5 India Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Congenital Hyperinsulinism Treatment Drugs Revenue by Type (2016-2026)
9.2 South America Congenital Hyperinsulinism Treatment Drugs Revenue by Application (2016-2026)
9.3 South America Congenital Hyperinsulinism Treatment Drugs Market Size by Country
9.3.1 South America Congenital Hyperinsulinism Treatment Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Market Size by Country
10.3.1 Middle East & Africa Congenital Hyperinsulinism Treatment Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Congenital Hyperinsulinism Treatment Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

...

【掲載企業】

Novo Nordisk、Eli Lilly、Fresenius Kabi、Taj Pharmaceuticals、Xeris Pharmaceuticals、Novartis、IVAX Pharmaceuticals、Sun Pharmaceutical、Chengdu Tiantaishan Pharmaceutical、Sihuan Pharmaceutical Holdings Group

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の先天性高インスリン症治療薬市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)(Global Congenital Hyperinsulinism Treatment Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。